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Non-standard abbreviations 
A1M – alpha 1 microglobulin 
EBB – Earle’s Bicarbonate Buffer 
DKK - Dickkopf-related protein 
DEA-NONOate – diethyl NONOate 
eNOS – endothelial nitric oxide synthase 
EPO - erythropoietin 
FABP1 – fatty acid binding protein 1 
FGR – fetal growth restriction 
fHbF – free fetal hemoglobin 
fHbF:HO-1 – free fetal hemoglobin : heme oxygenase-1 ratio 
FIHP – fetal-side inflow hydrostatic pressure 
HbF – free hemoglobin 
HBSS – Hank’s buffered saline solution 
HO – heme oxygenase 
HO-1 – heme oxygenase 1 
HPAECs – human chorionic plate artery endothelial cells 
IBC – individualised birthweight centile 
IL1α – interleukin-1 alpha 
L-NNA - Nω-nitro-L-arginine 
NO –nitric oxide 
TBM – tissue basement membrane 
TNFα – tumor necrosis factor alpha 
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Abstract 
Cell free hemoglobin (fHb) impairs vascular function and blood flow in adult cardiovascular disease. In this 
study we investigated the hypothesis that fetal fHb (fHbF) compromises vascular integrity and function in 
the feto-placental circulation, contributing to the increased vascular resistance associated with fetal growth 
restriction (FGR). Women with normal and FGR pregnancies were recruited and their placentas collected 
freshly post-partum. FGR fetal capillaries showed evidence of erythrocyte vascular packing and 
extravasation. Fetal cord blood fHbF was increased in FGR compared with normal pregnancies (P<0.05), 
whilst elevation of its ratio with HO-1 suggests failure of expected catabolic compensation, as occurs in 
adults. During ex vivo placental perfusion, pathophysiological fHbF concentrations significantly increased 
fetal-side microcirculatory resistance (P<0.05). fHbF sequestered nitric oxide in acute and chronic exposure 
models (P<0.001), whilst fHbF-primed placental endothelial cells developed a pro-inflammatory phenotype, 
demonstrable by activation of NFκB pathway, generation of IL-1α, TNFα (both P<0.05), uncontrolled 
angiogenesis and disruption of endothelial cell flow-alignment. Elevated fHbF contributes to increased feto-
placental vascular resistance and impaired endothelial protection. This unrecognised mechanism for fetal 
compromise offers a novel insight into FGR, and potentially unexplained associated poorer fetal outcomes 
such as fetal demise/ stillbirth. 
 
 
Keywords: endothelium, placenta, vascular compromise, blood flow resistance. 
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Introduction 
 
Fetal growth restriction (FGR) is the failure of a fetus to meet its genetically determined growth potential.(1) 
Whilst many cases lack an identifiable cause, FGR is strongly associated with fetal demise, and 
accompanies 50% of unexplained stillbirths.(2) Positive correlations between low birthweight, increased risk 
of adult cardiovascular disease and stroke have been documented, with growing evidence of the latent 
consequences of adverse prenatal programming.(3, 4)  
In healthy pregnancy, umbilical resistance, measured antenatally by umbilical artery Doppler velocimetry, 
correlates accurately with postpartum fetal-side ex vivo placental perfusion resistance.(5) The placental 
villous microcirculation is an important locus of vascular resistance and reduced feto-placental blood flow 
threatens fetal growth and survival.(5, 6) Ordinarily, the upward adjustment of placental blood flow across 
gestation is critical in meeting growth demands, and for development. However, in FGR these feto-placental 
adaptations can fail, restricting the feto-placental circulation and compromising placental function. In its 
severest form, antenatal umbilical arterial Doppler velocimetry reveals atypical waveforms, such as absent 
or reversed end-diastolic flow.(7-9)  
Under conditions of altered placental blood flow, fetal hemoglobin (HbF) is thought to be upregulated in an 
attempt to compensate for chronic hypoxia.(10, 11) This excess may be transferred to the maternal 
circulation in pre-eclampsia, a disease associated with FGR, where placentally-derived cell free fetal 
hemoglobin (fHbF) has also been reported.(12-14) Whilst the direct impact of fHbF on the fetal circulation 
remains unclear, it is proposed that erythrocyte behaviour is disturbed in FGR, with elevations of nucleated 
red cells defined in the placenta in as many as 89% of cases, even those devoid of Doppler anomalies.(15, 
16) Although difficult to substantiate in the fetus, perpetuated erythrocytes are known to rupture under 
modest elevations in vascular shear stress; conditions which, without doubt are present in FGR cases, and 
manifest by flow abnormalities on antenatal Doppler (17). Under these circumstances, free hemoglobin 
release is inevitable, but under normal homeostasis remains finely regulated.  
In the absence of innervation and autonomic regulation, the feto-placental unit is reliant upon humoral 
mechanisms for buffering feto-placental blood pressure.(18) Within this context, nitric oxide (NO) is critical 
for vasodilation and maintaining blood flow.(5, 18, 19) Whilst encapsulated in red cells, the NO scavenging 
capacity of hemoglobin is significantly reduced, by at least 1,000-fold.(20, 21)  However, in its extracellular 
(free) form, sequestration of NO by oxyhemoglobin occurs instantaneously. In the feto-placental circulation, 
compromised induction of endogenous heme-oxygenase (HO-1), as a primary heme-scavenging enzyme, 
could exacerbate this situation.(22) Upregulation of HO-1 in the term placenta is expected from previous 
work demonstrating a protoporphyrin-induced increase in HO-1 expression, most notably in the stem villous 
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vasculature. Attenuation of this pathway is already associated with increased TNFα-induced 
cytotoxicity.(23) 
We therefore hypothesise that cell free fetal hemoglobin is upregulated in the fetal circulation in growth 
restricted pregnancy, causing endothelial activation and vasoconstriction in the human feto-placental 
circulation in this disease. 
 
 
 
Materials and Methods 
 
Ethics: Tissues were acquired following informed written consent from women attending St Mary’s 
Hospital, Manchester (all subjects), UK. Ethical approvals were obtained from the Licensing committee: 
North West Research Ethics Committee (reference numbers: 08/H1010/55, 08/H1010/55 (+5), 
11/NW/0650). All experiments were performed in accordance with relevant guidelines and regulations. 
 
Research Volunteers: Placentas were obtained from normal singleton pregnancies. To define groups, an 
individualized birthweight centile (IBC) was calculated according to the GROW algorithm (Perinatal 
Institute, Birmingham, West Midlands, UK). Groups were normal or FGR.  FGR diagnosis was based on the 
Delphi-consensus definition as solitary parameter of IBC below the 3rd centile for gestation.(24) 
 
Reagents: Unless otherwise stated, reagents were supplied by Sigma-Aldrich (Poole, Dorset, UK). fHbF 
was extracted from whole umbilical cord blood and purified as described previously.(25) 
 
Feto-placental vascular appearance in FGR: An archive of stored transmission electron micrographs 
(TEMs) of freshly fixed placental tissue from FGR (N=15) were analyzed for endothelial morphology and 
erythrocyte distribution. For this analysis, specimens of placenta had been obtained immediately after 
delivery and a small piece of villous tissue excised from beneath the centre of the basal plate. This was diced 
into small fragments with a razor blade on dental wax and fixed for 4 hours at room temperature in 2-5 % 
glutaraldehyde in 0.1 M cacodylate buffer pH 7.4. The tissue was then rinsed three times over 24 hours in 
buffer containing 3 mM calcium chloride. Post-fixation was carried out in 1% osmium tetroxide (TAAB 
Laboratories Equipment Ltd, Aldermaston, Berkshire, UK) in 0.05M sodium cacodylate buffer pH 7.4 for 1 
hour at 4°C followed by a buffer rinsing step. The tissue was then dehydrated in an ascending alcohol series, 
treated twice with propylene oxide (TAAB Laboratories Equipment Ltd; 15 mins each) then left in a 1:1 mix 
of propylene oxide and TAAB epoxy resin for one hour at room temperature. It was then left overnight on a 
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rotator at 4°C in a mixture of 1:3 propylene oxide and epoxy resin and the following day given three 
changes of fresh resin at 45°C for one hour each before being embedded in gelatin capsules and polymerised 
for 72 hours at 60°C.  Semithin sections, 0.5µm thick, were cut on a ultramicrotome (LKB, Mount Holly, 
NJ, USA), stained with 1% toluidine blue in 1% borax, after which ultrathin sections were prepared with a 
glass knife, mounted on copper grids and stained with uranyl acetate and lead citrate. These were examined 
in an AEI EM6B electron microscope at an accelerating volage of 60kV and appropriate areas 
photographed. 
 
Measurement of Plasma fHbF and HO-1: A Vacutainer system with 21 gauge needle attachment was 
utilized as the standard collection method.  Umbilical vein blood was collected into a citrate tube without 
perturbations of flow during filling and the method standardised for collection from the cord vein insertion 
point, within 15 minutes of birth. This was followed by immediate centrifugation in the laboratory (within 
10 minutes of collection at 1500 x g x 10 minutes at ambient room temperature).  This method was 
determined following a stringent optimisation process to prevent iatrogenic hemolysis, including: different 
anticoagulants (EDTA, or citrate), the operating technique for venipuncture (closed-vacuum versus 21G 
needle and syringe technique), the venipuncture site and time lapsed prior to centrifugation.  A citrate 
collection method was associated with negligible artefactual hemolysis (median increased 0.05589 ug/ml + 
IQR 0.0687) and temporal standing for 20 minutes resulted in a modest increase in detectable fHbF (median 
0.1909 ug/ml + IQR 0.2230).  Early collection into a citrate tube with immediate processing resulted in a 
low hemolysis with tight variance.  
 
fHbF was measured using a sandwich-ELISA(26)
 
(Lund University, Lund, Sweden) in venous cord plasma 
of normal and FGR pregnancies.  Blood was taken at the cord insertion point and processed following the 
optimized method. Ninety six-well microtiter plates were coated with mouse anti-HbF antibodies (4µg/ml in 
PBS) overnight at ambient temperature. In the second step, wells were blocked for two hours using blocking 
buffer (1% BSA in PBS), followed by an incubation with HbF calibrator or the samples (normal n=12; FGR 
n=5 for 2 hours at ambient temperature). In the third step, HRP-conjugated mouse anti-HbF antibodies 
(diluted 1:5000) were added and incubated for 2 hours at ambient temperature. Finally, a ready-to-use 
3,3′,5,5′-tetramethylbenzidine (Life Technologies, Stockholm, Sweden) substrate solution was added, 
reaction was stopped after 20 minutes using 1.0 M HCl and the absorbance was read at 450nm using a 
Wallac 1420 Multilabel Counter (Perkin Elmer Life Sciences, Waltham, MA, USA). Where sufficient 
plasma was available, plasma HO-1 expression was measured by immunoassay (Enzo Life Sciences, Exeter, 
Devon, UK). HO-1 was used as denominator for matched fHbF concentrations (fHbF:HO-1 ratio), subject to 
plasma availability (n=12).   
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fHbF Assay Development: Human γ-chains were prepared by dissociation of purified HbF with p-
mercuribenzoate and acidic precipitation(27, 28). The absolute purity of HbF (from contamination with 
HbA), and of γ-chains (from contamination with α- and β-chains), was determined by non-denaturing PAGE 
followed by blotting with purified anti-human γ-chain (26, 29). Mouse antibodies to human γ-chains, 
specific for HbF, were produced and purified by AgriSera AB (Vännäs, Sweden). Anti-HbF antibodies were 
then conjugated with horseradish peroxidase (Lightning-Link HRP, Innova Biosciences, Cambridge, 
Cambridgeshire, UK) to provide a quantitative indirect reporter. 
 
Additional biochemical validation of altered fHbF fetal plasma status in FGR: In testing the hypothesis 
that fHbF is elevated in FGR, additional assays were performed on the same fetal plasma samples to validate 
expressional or hemolytic changes that might have occurred in vivo linked to changes in plasma fHbF status, 
including erythropoietin (EPO), hemopexin, haptoglobin and α-1 microglobulin (A1M).  Measurement of 
lactate dehydrogenase (LDH) was also performed as a validation against artefactual hemolysis and 
undertaken according to manufacturer’s instruction.  All kits were from Abcam (Cambridge, 
Cambridgeshire, UK).   
 
Effect of fHbF on feto-placental vascular resistance tested by ex vivo human dual placental perfusion: 
Normal placentas (≥37 weeks) were perfused in open circuit using ex vivo dual circuit perfusion, as 
previously described in an adaptation of the model developed by Schneider et al.(30, 31) Briefly, fetal-side 
inflow hydrostatic pressure (FIHP) was monitored using a Medex pressure transducer (Digitimer, Welwyn 
Garden City, Hertfordshire, UK) and recorded using a Nanologger (Gaeltec Nanologger, Isle of Skye, Inner 
Hebrides, UK) following perfusion with Earle’s Bicarbonate Buffer (EBB). Fetal-side flow rate was 
determined following assurance that NO-evoked, flow-mediated vasodilation was effective, by 
incrementally adjusting the flow rate and observing temporal flow mediated vasodilation. Minimum 
acceptable fetal-side venous return was ≥80% of arterial inflow. Maternal-side perfusion at 14mL/min was 
started when steady-state FIHP was reached and delivered evenly into the intervillous space by five 
cannulae.   
 
fHbF was introduced from a syringe driver (Precidor model, Infors AG, Basel, Switzerland) into the fetal 
inflow-line through a pre-pump injection port, obtaining FIHP responses to a pathophysiological dose-range 
of fHbF found in fetal plasma (0.01-1.0mg/mL). Following completion, the fetal-circuit was equilibrated 
with 100µmol/L Nω-nitro-L-arginine (L-NNA), to inhibit endothelial nitric oxide synthase (eNOS) and the 
dose response to fHbF repeated.  For each dose of fHbF and vehicle, FIHP within the ex vivo dual perfused 
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placenta was compared to its previous steady-state, with alterations in resistance reported as an absolute 
change.  As proof of concept, NO sequestration was corroborated in vitro using a published method, 
0.3mg/mL fHbF was reacted with 120µmol/L diethyl-NONATE (DEA-NONOate), as further proof of NO 
catabolism with fHbF in the feto-placental circulation and a spectrophotometric survey conducted. 
 
Effect of fHbF on shear-stress evoked endothelial NO synthesis: Human placental arterial endothelial 
cells (HPAECs) from normal pregnancies were isolated, cultured and characterized using an established 
method.(32)  Confluent HPAECs were subjected to 20 dynes/cm
2
 shear stress for 48 hours (Ibidi, Munich, 
Bavaria, Germany). Nitrite, the stable breakdown product of NO, was measured in the flow-conditioned 
medium using the Griess reaction (Thermo Fisher, Loughborough, Leicestershire, UK). 100 μl of 0.8% 
(w/v) VCl3 was added to each well of a 96 well clear plate as a nitrite reduction step.  Vanadium trichloride 
(VCl3) was selected as the chemical reductant according to a previously published method (33).  Method 
validation was performed in our laboratory using serial dilutions of silver nitrate to yield a satisfactory linear 
plot with the linear regression equation y = 0.103+0.002x (R2 = 0.98; p=<0.0001).  Greiss reaction was then 
performed according to the standard manufacturer’s method.  Lysates were used to analyze proteome 
dysregulation (see below). 
 
Effects of fHbF on in-situ vascular morphology: Chorionic artery plate sections from placentas from 
normal pregnancy were exposed to 0.6mg/mL fHbF, and cultured at 37
o
C for 48 hours. Control vessels were 
exposed to HBSS vehicle. Vessels were fixed in sodium cacodylate buffer (0.1M) pH 7.4 and the lumen 
exposed by longitudinal incision. Specimens were processed for scanning electron microscopy (SEM). 
 
Effect of fHbF on HPAEC angiogenesis: HPAEC growth on Matrigel, a placental-derived basement 
membrane matrix (Corning, Bedford, Bedfordshire, UK) was utilised to assess angiogenesis. HPAECs (2.8 x 
10
4
 cells/mL) were observed after 24 hours’ incubation with 0.3mg/mL fHbF or PBS as control. HPAECs 
assembled into capillary-like tubule networks on this matrix.  Tubule formation was quantified by 
microscopy using systematic examination of seven fields per view. Image Pro 7 software (MediaCybernetics 
Inc, Silver Spring, MD, USA) was used to analyse the tubule formation in the presence of fHbF (0.3mg/mL) 
or PBS vehicle. These values were then multiplied together, which was used as a net measure of 
angiogenesis. 
 
Proteomic endothelial ‘cell stress’ array and inflammatory pathway investigation:  Flow-conditioned 
HPAEC cells were lysed (see above) and harvested into ice-cold RIPA buffer. Standardization was 
performed for equivalent protein loading (micro-BCA kit; Thermo Fisher). Cell stress array blotting was 
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undertaken according to manufacturer’s instructions (R&D Systems, Abingdon, Oxfordshire, UK). A 
proteomic profile was obtained from fHbF-exposed and unexposed cells.   
For assessment of NFκB and cytokine release, HPAECs were exposed to fHbF (0.07-1.2mg/mL) in separate 
static culture and cells were fixed in methanol and immunofluorescence stained for NF-κB p65 and DAPI. 
Cells were permibilised with 0.5% TritonX-100 (in PBS) for 30 minutes and washed with PBS before 0.01% 
sodium borohydride in TBS.  This process was repeated three times before blocking with buffer (TBS/5% 
normal swine solution) and maintained for 1 hour at 21
o
C. Cells were incubated overnight at 4
o
C with NF-
κB p65 1° antibody (Cell Signalling Technology, Leiden, The Netherlands) diluted 1:400 (TBS/1% BSA). 
Anti-Rabbit IgG (Dako, Stockport, Cheshire, UK) at 1:50 dilution was used as a negative control. Cells were 
assessed using fluorescence microscopy (Ziess, Cambridge, Cambridgeshire, UK) and NF-kB translocation 
assessed using a qualitative method with DAPI overlay, and blinded to fHbF exposure dose on a three tier 
scale (definite, intermediary or negative activation).   
  
HPAEC cells exposed to fHbF under static culture conditions were lysed using radioimmunoprecipitation 
assay buffer for ELISA studies using DuoSet® kits (R&D Ssystems, MN, USA).  A panel of NFkB-related 
inflammatory cytokines and triggers to the canonical route of NFkB activation (IL1α, IL1β, TNFα) were 
measured. ELISAs were performed on cell lysates, and undertaken according to the manufacturer’s 
instruction. Protein quantity was measured using a Bio-Rad DC Protein Assay (Bio-Rad, Watford, 
Hertfordshire, UK), allowing adjustment for protein content (34). As a standardising method, results were 
analysed as a fold change from the control in each cell line. 
Statistics: Data, tested for normality and analyzed using GraphPad Prism (La Jolla, CA, USA), are 
expressed as either mean +/- SE or median +/- range. Statistics are qualified throughout. P values <0.05 
were considered significant. 
Data availability: The datasets generated and/or analyzed during the current study are available from the 
corresponding author on reasonable request. 
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Results 
 
Patient demographics: An extensive listing of separate pregnancy cohorts relating to each study group is 
given (Table 1). 
Feto-placental vascular characteristics in FGR: Qualitatively, capillary avascularity was more common 
in FGR placentas, with erythrocyte vascular packing and extravasation restricted to FGR (Figure 1) leading 
us to investigate fHbF and HO-1 handling (see below). 
fHbF is elevated in FGR cord blood: fHbF concentrations were significantly greater (Figure2a), whilst 
HO-1 concentrations were lower (Figure 2b), in fetal plasma from FGR compared to normal pregnancies 
(NS). The ratio of fHbF : HO-1 was significantly higher in FGR (Figure2c), with improved separation of 
the groups. Delivery mode had no significant effect on fHbF concentration (FGR group: Mann Whitney test 
P = 0.999; in the normal group the single normal vaginal delivery case had a fHbF plasma value of 0.73 μM, 
close to the median of 0.85 μM).   
Additional biochemical validation of altered fHbF fetal plasma status in FGR: EPO and A1M levels 
were higher and hemopexin was lower in the cord plasma of FGR pregnancy (P<0.01, P=0.05 and P<0.01, 
respectively) compared to normal pregnancy; whilst haptoglobin levels were not different between the 
groups, (Supplementary Figure 1).  LDH release was not different between groups: normals: 9.63 (7.22, 
23.64; N=18); and FGR: 12.49 (5.39, 20.3; N=19); data shown as median (25
th
, 75
th
 centiles); Mann-
Whitney test: P= 0.663. 
fHbF elevates feto-placental resistance through NO scavenging: fHbF caused a significant dose-
dependent increase in FIHP, reflecting elevated downstream resistance in the placental villous 
microcirculation (Figure3A & B). Repeating the same dosing regimen in the presence of L-NNA (100μM) 
as an eNOS inhibitor, the starting baseline pressures were artificially elevated as expected, but peak 
elevations in FIHP were significantly attenuated, suggesting fHbF sequesters NO from the feto-placental 
circulation when it is present.  As further corroboration in a separate experiment, we found the in vitro 
addition of DEA-NONOate, an NO donor, rapidly transformed oxyhemoglobin to methemoglobin 
(Supplementary Figure 2), demonstrating sequestration by fHbF. 
fHbF reduces NO bioavailability in flow-conditioned endothelial cells: fHbF at FGR cord blood 
concentrations reduced total NO bioavailability (total NOx) compared to vehicle, as determined by the 
Griess reaction (Figure 3C). 
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fHbF disrupts endothelium laminar morphology: Exposure of placental chorionic plate arteries to 
0.6mg/mL fHbF for 48 hours resulted in a dysmorphic luminal endothelial surface, with extensive cell-
blebbing not observed in control arteries (Figures 4B & 4A, respectively). Whilst a dysregulated 
morphology could only be found in some zones of the chorionic plate artery endothelium exposed to fHbF, 
the PBS exposed control vessels were completely normal in appearance, as verified by independent 
observers blinded to the groups. Light microscopy of flow-conditioned HPAECs from normal pregnancies 
showed that 0.3mg/mL fHbF reduced cell density and disrupted normal cell morphology, preventing cell 
alignment with flow compared to controls (Figure 4D & C, respectively). 
fHbF activates the feto-placental endothelium: fHbF promoted HPAEC angiogenesis on Matrigel; 
suggested by increased ‘tubule’ branching intensity (Supplementary Figure 3). This was consistent with 
the findings from a ‘cell stress’ proteome array for fHbF-exposed HPAECs. Within this array, several 
proteins associated with enhanced angiogenesis (DKK-4), fatty acid uptake, lipid peroxidation, vascular 
remodeling (FABP-1), and inflammation (FABP-1 and NFkappa-B) were up-regulated (fHbF 0.3mg/mL; 
Table 2).  These effects were confirmed in an investigation of endothelial nuclear translocation of NFκB 
and cytokine release.  1.2 mg/mL fHbF (the high-end FGR fetal plasma level) evoked NFκB translocation to 
HPAEC nuclei within two and a half hours of exposure in static culture (Figure5Aiii & iv.). This was not 
seen in the vehicle controls (Figure 5A i.) or at the median value of normal fetal plasma levels (Figure 5A 
ii.).  Evidence of activation of NFκB targets was provided by a dose response increase in the release in 
interleukin-1α and TNFα (Figure 5B & 5C respectively) from HPAECs exposed to fHbF doses 
≥0.2mg/mL. 
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Discussion 
We found fHbF is elevated in the fetal circulation of FGR pregnancy, commensurate with modifications to 
levels of biochemical markers acting as endogenous heme handling agents. Elevations in fHbF levels in 
FGR plasma are likely to be inconsequential of hemolysis, since fetal plasma LDH levels were not different 
between groups. Such elevated levels of fHbF caused vasoconstriction in the ex vivo human placenta dual 
perfusion model, by sequestering NO. This was confirmed biochemically using NO donation to oxy-fHbF 
using spectrophotometry and in a HPAEC cell-flow model, where liberated levels of NO were reduced when 
exposed to fHbF. Furthermore, pathophysiological levels of fHbF evoked endothelial inflammation in 
HPAECs, confirming cell blebbing seen in ex vivo chorionic plate artery cultures. Severe reductions in feto-
placental blood flow may threaten fetal growth and pregnancy viability.(35) Although the pathogenesis of 
FGR is unclear, feto-placental vascular compromise is implicated, manifesting as altered umbilical blood 
flow in the severest cases.  
Elevated fHbF in the feto-placental circulation and heme handling mechanisms: HbF is a helical 
tetramer composed of a  porphyrin ring and two attached alpha and two gamma globin subunits (α2γ2) (17) 
encoded by alpha (Hb-α) and gamma (Hb-γ) globin genes; both expressed within the placental villi.(12) A 
twenty-fold upregulation in Hb-α in umbilical cord blood and amniotic fluid occurs in FGR pregnancies 
compared to normally grown equivalents, as well as increased fHbF mRNA in maternal blood, implying a 
strong hematological component to the disease.(10, 17)  Indeed as a marker of chronic feto-placental 
hypoxia, increased hematocrit and erythropoiesis has already been reported by several authors but never 
before linked to hemolytic intravascular events. (11, 36, 37) Martenelli et al. have described how increased 
hematocrit in the cord of babies small for gestational age correlated with increased pulsatility index, as a 
measure of high feto-placental resistance.(37) In support of this notion, we have now demonstrated higher 
circulating concentrations of fHbF in cord blood in FGR and have provided convincing evidence of multiple 
deleterious effects of this fHbF within the feto-placental vasculature.  Using an optimised method to 
minimise artefactual hemolysis, the median concentration of fHbF in fetal cord plasma was five times 
greater than that in the normal pregnancy group, suggesting a heme-generating insult.  We found delivery 
mode had no effect on fetal plasma fHbF levels that might have been envisaged to arise through the 
mechanical effects of labour.  
HO-1 enzyme, an inducible pathway of heme degradation, is present in the human placenta.(23, 38) Within 
cord blood plasma, we demonstrated that the expected vasculo-protective up regulation of HO-1 to 
protoporphryrins, reported elsewhere, fails to occur in FGR.(23) Furthermore, circulating HO-1 is known to 
reflect tissue contributions in similar vascular pathologies where free hemoglobins predominate.(39)  The 
higher levels of fHbF and the absence of HO-1 up regulation in the cord blood of FGR pregnancies served to 
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exaggerate the fHbF : HO-1 ratio in FGR, implying uncoupling of HO-1 from excessive circulating fHbF. 
We suggest that a reduction in catabolic potential for fHbF could predispose the fetus to vascular 
compromise.   By contrast in the normal group there was a tight clustering of the fHbF : HO-1 ratio within a 
finite low range, with downward correction of fHbF values at the upper range, suggesting an appropriate 
‘housekeeping’ response of HO-1 to the prevailing intravascular hemoglobin in normal pregnancy.  We 
therefore propose a novel use of a ‘fHbF:HO-1 ratio’ as a tool for assessing feto-placental heme-handling. 
Murine models illuminate biological consequences of failed HO-1 induction. HO-1 heterozygotes (+/- HO-
1) exhibit FGR, despite increased endothelial and inducible nitric oxide synthase.(38) Paradoxically, other 
human studies of FGR, including our own(5) show increased expression of NOS and increased NO 
metabolic products in the umbilical cord, consistent with the mouse model; but the failed compensatory 
response of HO-1 to excess fHbF and the  fHbF:HO-1 mismatch we have now demonstrated in FGR 
pathology provides better insight to account for this apparent discrepancy.
(5, 40, 41)
  
 
In validating increased fHbF levels in the FGR group as being a true in vivo event we measured the levels of 
other biochemical markers including some linked to cell free heme handling. The significant elevation in 
EPO levels in FGR is in keeping with placental hypoxia frequently observed in this disease; a process that 
may potentiate erythrogenesis. That said, our finding of no difference in LDH between groups indicates that 
a significant contribution of the fHbF plasma elevation in some FGR cases could arise through a mechanism 
of non-marrow hematopoeisis and independent of mechanical hemolysis.  That embryonic tissue itself has 
an intrinsic capacity for α an γ globin production is a finding previously demonstrated in preeclampsia and 
other disciplines, and our data now supports this notion in FGR.(12, 42)  Finding a reduction in fetal plasma 
hemopexin in FGR suggests that most of the circulating levels have been depleted through chaperoning fetal 
heme to the maternal liver. Fetal plasma hemopexin levels are normally lower than adult levels, 
consequential of a shorter half-life of fetal erythrocytes compared to adult erythrocytes and a greater need 
for heme detoxification of the fetal circulation (43). A further reduction of hemopexin in FGR fetal plasma 
suggests an even higher in vivo heme load in this disease.   An elevation in fetal plasma A1M could be 
indicative of an attempt to compensate for higher heme levels in FGR, in keeping with similar observations 
in the maternal circulation in preeclampsia, where fHbF is also elevated (44). 
 
fHbF evoked changes to blood flow resistance in the placenta: Within the ex vivo perfused human 
placenta, fHbF increased feto-placental blood flow resistance through an NO-dependent mechanism. The 
response was dose-dependent and confirmed through in vitro testing with an NO donor, with the most 
prominent effects observed at the pathophysiological levels of fHbF found in FGR cord plasma. 
Nevertheless, poor recoverability from vasoconstriction also suggests a secondary (NO-independent) 
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mechanism is at play. This non-recoverable vasoconstriction may be linked with the pronounced endothelial 
blebbing evoked by fHbF in chorionic plate vessels. 
With loss of morphological conformity in flow-cultured HPAECs exposed to fHbF, alongside an 80% 
reduction in detectable NO, we propose that this atypical fHbF-evoked endothelial topography causes 
elevated feto-placental resistance and a decline in placental function. Increasing the length of the pathway in 
the placental transfer of hydrophilic nutrients is a separate consideration to any other additional 
dysregulation that might occur to the facilitated and active transport processes of nutrients across the 
syncytiotrophoblast. Here, we refer to the under-explored effects on the feto-placental endothelium.(45) 
Such dysregulated endothelial morphology is a feature of rhesus incompatibility of the new-born, another 
fHbF-laden vascular disease, associated with cytoplasmic blebs projecting from the endothelial cells of 
terminal villous capillaries with concomitant basement membrane thickening.(46) 
 
This small cohort study of FGR cases was diagnosed on solitary Delphi-consensus of birthweight centile 
<3
rd
 centile and provides preliminary evidence that fHbF is elevated in some cases, resulting in probable 
detrimental effects on fetoplacental vascular health and homeostasis in vivo.(24) Recruitment was inclusive 
of a wide scope of FGR aetiologies, but omitted suspected chromosomal-related disorders and cases of 
infection. Future studies aimed at investigating the direct association of elevated fHbF levels with 
dysregulated fetoplacental blood flow would benefit from the targeted recruitment of pregnancies with a 
spectrum of abnormal uterine and umbilical Dopplers, and those with additional objective evidence of fetal 
compromise indicated by abnormal middle cerebral artery and or Ductus venosus Dopplers and/or placental 
hypoxemia indicated by elevated cord blood erythropoietin levels and lactate 
fHbF causes vascular inflammation in the placenta: Additionally, we noted numerous translational 
responses to fHbF, indicative of an altered endothelial proteome. In a cell stress array of HPAECs from a 
cell flow model and from time-lapse results of a further HPAEC static culture model, we found that nuclear 
translocation of NFκB occurred and its expression was-up regulated. NFκB is a known  transcriptional 
regulator implicated in atherosclerosis.(47) Heme-activation of NFκB is known to occur during in vitro 
culture of human aortic smooth muscle cells,(48)  but until now, it was unclear whether fHbF would invoke 
similar responses in the feto-placental vasculature. Our results suggest NFκB-dependent activation of 
cytokines occurs in fHbF exposed HPAECs.  Both IL-1α and TNFα were significantly increased following 
fHbF exposure and NFκB nuclear translocation. To contextualize this, we suggest that a secondary NO-
independent vasoconstriction observed in the perfused placenta might be explained by NFκB-dependent 
endothelial inflammation. Other notable directional responses in the cell stress array included a significant 
induction of the pro-angiogenic mediator DKK-4, an observation which paralleled increased tubule 
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formation for fHbF-exposed HPAECs grown on Matrigel. There was also an increase in FABP-1 synthesis; 
a mediator of lipid handling, and a transcriptional regulator previously implicated in FGR.(49, 50). 
Hypothesised sequelae of events leading to poor pregnancy outcome: We propose a novel mechanism 
whereby unchecked fHbF within the human placenta, and potentially the fetus, establishes a vicious spiral of 
events beginning with NO sequestration. This significantly contributes to vasoconstriction and reduced 
vasodilatory paracrine signalling, promoting vaso-occlusion with localised erythrocyte extravasation. In the 
absence of adequate heme-handling capacity (HO-1), elevated fHbF levels provokes vascular inflammation, 
endothelial stress, proliferative placental angiogenesis and activation of a cytokine-dominated immune 
response. Figure 6 illustrates this potential route to feto-placental compromise. With prolonged or severe 
hematologic dysfunction, the protective defences of the fetus become fully ablated with wholesale vascular 
collapse and fetal demise. Indeed, work from our laboratory shows prominent avascularity as a feature of 
peripheral lobules in FGR pregnancy (51). We therefore consider this mechanism a previously unrecognised 
pathway to FGR and potentially stillbirth. This knowledge will lead to future strategies to identify and treat 
failing pregnancies associated with incapacity to handle an elevated fetal heme load. 
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Figure legends 
 
Figure 1: TEM image from an FGR case exhibiting luminal packing and extravasation of fetal 
erythrocytes.  Key: E=erythrocyte, CL=capillary lumen, VS=villous stroma and black arrowheads represent 
the demarcation between VS and tissue basement membrane. 
 
Figure 2. The cell free fetal haemoglobin (fHbF) and heme oxygenase-1 (HO-1) status in the fetal 
plasma of normal and fetal growth restricted (FGR) pregnancy groups.  
Showing significant normal (●) and FGR (■) group differences in (a) fHbF fetal plasma levels (box and 
whiskers plot; medians (25
th
 & 75
th
 centile): 0.054 (0.038 & 0.094) & 0.222 (0.072 % 0.476) mg/mL; (N = 
25 & 16, respectively; Mann-Whitney: *P = 0.013); (b) HO-1 fetal plasma levels (box and whiskers plot; 
medians (25
th
 & 75
th
 centile): 0.006 (0.003 & 0.011) & 0.004 (0.000 & 0.007) ng/ mL (N=14 & 8, 
respectively; Mann Whitney: NS); (c) fHbF : HO-1 ratio (box and whiskers plot; median (25 & 75
th
 centile): 
9542 (680 & 16254) & 90493 (21056 & 521262), (N = 14 & 8, respectively; Mann-Whitney: ***P < 0.001).   
 
Figure 3: NO sequestration by fHbF in acute and chronic ex vivo and in vitro models. (i) Effects on 
fetoplacental flow resistance in the ex vivo perfused placenta (n=8), shown as a representative FIHP trace 
(Figure 3A). A significant dose response in FIHP to fHbF occurred (Figure 3B; one-way ANOVA: P≤0.05; 
downward arrows: incremental doses of fHbF: control-EBB, 0.01, 0.03, 0.06, 0.1, 0.3, 0.6 and 1.0mg/mL, in 
the absence (Phase 1) and presence (Phase 2) of the eNOS inhibitor, L-NNA (100μmol/L); solid squares 
represent  four minute delivery of fHbF). fHbF could not evoke significant peak elevations in resistance 
when NO production was absent (Figure 3B; ; mean±SE; Kolmogorov-Smirnov: P = 0.8571) compared to 
when it was present (; mean-SE; two-way ANOVA: #≤0.001; Dunnett’s post-hoc analysis: 0.6mg/mL and 
1.0mg/mL levels, *P≤0.05 both; Kolmogorov-Smirnov: P = 0.4286). (ii) fHbF reduced nitric oxide 
bioavailability in flow-cultured HPAECs after 24 and 48 hours (Figure 3C; ) compared to vehicle (PBS) 
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control treated cells (Figure 3C; ; n=6 cell lines for each group; one-way ANOVA P ≤0.01, Sidak’s post-
hoc test: *P≤0.05; ***P≤0.001; median and range shown). 
 
Figure 4: fHbF evoked changes in endothelial morphology. SEM images of the luminal endothelial 
surfaces of human placental chorionic plate arteries: exposed in situ for 48 hours to HBSS control (A), or 
fHbF (0.6mg/mL; B); scale bar = 200 μm. Light microscopy of HPAECs grown under flow (20 dynes/cm2; 
48 hours) and exposed to either PBS control (C) or 0.3mg/mL fHbF; scale bar = 50 μm (D). 
 
Figure 5: fHbF evoked endothelial activation. Representative images of fHbF induction of NFκB nuclear 
translocation (green fluorescent dye); confirmed by DAPI staining - a) in static HPAEC culture at 1 hour; 
doses selected were 0 (i; control; DAPI overlay shown); 0.07 (ii; median normal fetal plasma level), 0.2 (iii; 
median FGR fetal plasma level); and 1.2mg/mL (iv; high-end FGR plasma levels); n=4 normal HPAEC cell 
lines. fHbF induction of acute pro-inflammatory cytokine release into HPAEC static cultured conditioned 
medium at 24 hours for IL1α (b; one-way ANOVA: P = 0.0002; Bonferoni post-hoc test compared to 
control: **P > 0.01, ***P > 0.001; Kolmogorov-Smirnov: P > 0.100, all concentrations; N = 7) TNFα (c; 
Friedman: P = 0.0006;  Dunn's multiple comparison test, compared to control: ***P > 0.001; N = 7).  
  
Figure 6: Schematic of the ‘fHbF vascular demise spectrum’. fHbF excess occurs as a response to feto-
placental hypoxia and de novo production in the feto-placental unit[1] (12). This overwhelms primary 
vasculoprotective defences and heme-scavenging systems including haptoglobin, hemopexin, albumin and 
α1 microglobulin[2]. Nitric oxide (NO) sequestration occurs[3], causing increased vascular resistance[4], 
reduced feto-placental blood flow[5], placental microvascular congestion, and feto-placental 
hypertension[6]. Endothelial cells lose structural integrity[7]. Disturbed lipid handling may contribute to 
accelerated thrombosis and vascular occlusion[8]. As oxygen and nutrient delivery becomes compromised, 
fetal growth restriction (FGR) is a highly plausible clinical end point of vascular demise. Stillbirth may 
result when placental insufficiency passes an extreme threshold of diminished feto-placental perfusion[9]. 
Figure 1
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Figure 4
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Table 1. Research volunteer demographics 
A: fHbF cord blood ELISA: 
group normal (n=24) FGR 
(n=13) 
significance 
(P) 
    
maternal age 
(years) 
32 
(26-38) 
29 
(23-33) 
 
NS(0.213)a 
    
mode of delivery:       
NVD 1 5      
CS 23 8      
parity 1.00 
(0.25-1.00) 
0 
(0.00-1.00) 
NS (0.091)a     
GA (weeks) 39.1 
(39.0-39.4) 
38.5 
(35.7-39.0) 
0.028a     
BW (g) 3400 
(3191-3718) 
2420 
(1868-2580) 
≤0.0001a     
BMI 27(24-32) 25 (22-30)      
IBC 49.5 
(30.7-72.2) 
1.7 
(0.5-2.5) 
≤0.0001a     
 
B: other experimental data (all normal pregnancies): 
study: fHbF ex vivo 
perfusion 
 
(N=8) 
HPAEC 
Griess 
 
(N=8) 
SEM 
analysis 
 
(N=3) 
HBAS 
 
 
(N=5) 
HPAEC 
proteome 
array 
(N=3) 
HPAEC 
NFkB 
ELISA 
(N=4) 
HPAEC 
ELISA 
 
(N=7) 
maternal age 
(yrs) 
32 
(24-37) 
33 
(26-43) 
29 
(24-39) 
26 
(23-33) 
31 
(25-33) 
29 
(26-33) 
29 
(23-38) 
mode of delivery:       
NVD 2(25%) 1(12.5%) 0(0%) 1(20%) 1(33.3%) 0(0%) 0(0%) 
CS 6(75%) 7(87.5%) 3(100%) 4(80%) 2(66.6%) 4(100%) 7(100%) 
parity 0(0-3) 0(0-2) 1(1-2) 1(0-2) 1(0-1) 2(1-3) 1(0-3) 
lobule weight 
(g) 
 
 61 (27-89) 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
GA (weeks) 40.0 39.1 39.0 39.4 39.6 39.6 38.1 
(38.0-42.1) (38.1-39.7) (37.3-39.1) (38.1-40.0) (39.0-40.0) (39.0-40.0) (35.8-39.8) 
BW (g) 3320 
(2946-3960) 
3390 
(2620-3935) 
3094 
(3010-3484) 
3800 
(3145-3935) 
3740 
(3145-3800) 
3480 
(2890-3834) 
3530 
(2420-3840) 
IBC 44 
(27-86) 
65 
(22-88) 
73 
(53-81) 
85 
(26-88) 
82 
(26-85) 
59 
(26-89) 
74 
(17-99) 
 
Data is presented as median (IQR). Data are presented as median (IQR) and comparative analyses undertaken by Mann 
Whitney U test a.  FGR; fetal growth restriction; NVD: normal vaginal delivery; CS: caesarean section; GA: gestational age; 
BW: birthweight; IBC: individualized birthweight centile; SEM: scanning electron microscopy; HBAS: fHbF branching 
angiogenesis study; HPAEC: human placental arterial endothelial cells; SEM: scanning electron microscopy.  There was 
some overlap of cases for HPAEC work where three cases represented in the HPAEC proteome array group also occurred in 
the angiogenesis (HBAS) arm, and one of these same cases also occurred in the HPAEC NFkB ELISA panel.  All of the 
NFkB ELISA cases are also represented in the HPAEC cytokine ELISA work due to overlap between products of the same 
HPAEC experiments utilised for different methods. 
 
Table 2. The effect of fHbF (4.7µmol/L) on the stress-array protein phenotype in HPAECs under flow-
cultured conditions.   
protein % increase from 
vehicle (*>50%, 
**>100%) 
roles / associations references 
FABP1 ** 
 
coronary atherosclerotic burden 44 
DKK-4 * Pro-angiogenic, evidence in colonic cancer 45 
Hif-1alpha * 
 
Pro-angiogenic; vascular dysfunction in ischemia-
reperfusion injury by reducing bio-available NO 
46 
 NFkappaB1 * 
 
Pro-apoptotic; represses bcl-2 transcription; 
promotes inflammatory cytokines; dissociates tight-
junctional complexes – represses occludin 
expression 
39, 47 
Abbreviations:  DKK-4 = Dickkoph WNT signalling pathway 4; FABP1 = fatty acid binding protein 1; Hif-1alpha = 
hypoxia-inducible factor 1 alpha; NFKappaB1 = nuclear factor kappa-light-chain-enhancer of activated B cells. 
 



